What are the morphological and immunophenotypic features of lymphoblasts?

Lymphoblast Features: Morphological and Immunophenotypic Characteristics

Lymphoblasts are immature lymphoid cells characterized by specific morphological features including intermediate-to-medium size, high nucleocytoplasmic ratio, condensed chromatin, indistinct nucleoli, and scant basophilic cytoplasm, with definitive classification requiring comprehensive immunophenotyping to distinguish B-cell from T-cell lineage. 1

Morphological Features

General Cytologic Characteristics

• Cell size: Small to medium-sized blasts with intermediate dimensions (similar to histiocyte nucleus size) 1
• Nuclear features: Round nuclei with relatively coarse chromatin, multiple small nucleoli (often indistinct), and more condensed chromatin compared to myeloid blasts 1, 2
• Cytoplasm: High nucleocytoplasmic ratio with scant cytoplasmic rim that is moderately basophilic 2
• Cytoplasmic characteristics: Usually agranular and free of vacuoles (except in mature B-cell ALL/Burkitt lymphoma where clear cytoplasmic vacuoles may be seen on Wright-Giemsa staining) 3, 2
• Cell-to-cell variability: Low grade of morphologic variation between cells 2

FAB Classification Morphology

The French-American-British (FAB) system categorizes ALL into L1, L2, and L3 subtypes, though only L3 identification carries major clinical importance 2:

• L1 morphology: Small uniform cells with absent to slight nuclear convolutions 4
• L2 morphology: Larger cells with more pleomorphism, presence of nuclear convolutions 4
• L3 morphology: Medium-to-large cells with intensely basophilic, moderately abundant cytoplasm and prominent cytoplasmic vacuolation in bone marrow 2

Immunophenotypic Features

B-Cell Lineage Lymphoblasts (Precursor B-ALL)

Precursor B-cell ALL constitutes approximately 88% of childhood cases and 75% of adult cases 1

Core B-Cell Markers

• Positive markers: CD19, CD22, CD79a (virtually always positive) 1, 5
• Additional markers: PAX5, CD24 (positive in most cases) 5
• Terminal deoxynucleotidyl transferase (TdT): Positive in precursor B-ALL 1
• CD20 expression: Variable, present in approximately 50% of B-cell lineage ALL in adults, with higher frequency (>80%) in mature B-cell ALL 1

Maturation Stage-Specific Markers

The immunophenotype varies according to B-cell maturation stage 1:

• Pre-pre-B-cell (pro-B-cell) ALL:

  • TdT positive
  • CD19/CD22/CD79a positive
  • CD10 negative
  • Surface immunoglobulins negative 1

• Common B-cell ALL:

  • CD10 positive (common ALL antigen) 1

• Pre-B-cell ALL:

  • Cytoplasmic immunoglobulins present
  • CD10/CD19/CD22/CD79a positive 1

• Mature B-cell ALL:

  • Surface immunoglobulins positive
  • Clonal lambda or kappa light chains positive
  • TdT negative 1
  • CD20 expression in >80% of cases 1

Negative Markers

• CD3: Negative (T-cell marker) 3
• TdT: Negative in mature B-cell ALL only 1, 3

T-Cell Lineage Lymphoblasts

T-cell lineage ALL constitutes approximately 25% of adult cases and 12% of childhood cases 1

Core T-Cell Markers

• Cytoplasmic CD3: Present in T-cell lineage blasts 1
• Surface CD3: Present in mature T cells (only reliable lineage-specific marker) 5
• Variable expression markers: CD1a, CD2, CD5, CD7 (variable expression patterns) 1
• TdT: Typically positive 1, 5
• CD52: May be expressed in 30-50% of T-cell lineage ALL in adults 1

T-Cell Subset Markers

• CD4 and CD8: Variable expression patterns 6
• OKT4 (CD4): Some cases positive 6
• OKT8 (CD8): Some cases positive 6

Early T-Cell Precursor (ETP) ALL

This distinct biologic subtype is associated with poor clinical outcomes and characterized by 1, 7:

• Absent markers: CD1a, CD8
• Weak expression: CD5 (<75% positive lymphoblasts)
• Positive markers: One or more myeloid or stem cell markers on ≥25% of lymphoblasts 1

Additional Immunophenotypic Markers

Proliferation and Differentiation Markers

• Ki-67: ≥95% positive in Burkitt lymphoma/leukemia; variable in other lymphoblastic neoplasms 3
• CD34: Variable expression (stem cell antigen) 5
• CD45: May be absent 5

Aberrant Marker Expression

Myeloid-associated antigens such as CD13 and CD33 may be expressed in ALL, but their presence does not exclude the diagnosis of ALL 1, 4. Aberrant markers correlate with specific morphologic features:

• CD117 and CD33 positive cases: Show L2 morphology with nuclear convolutions 4
• CD79a positive cases: Show L1 morphology with absent-to-slight convolutions 4

Critical Diagnostic Considerations

Minimum Diagnostic Requirements

Morphology and flow cytometry are the minimum methodologies required to yield diagnostic information, especially in critically ill patients 3. Malignant fluid cytology and flow cytometry may suffice when tissue biopsy is not feasible 3.

Differential Diagnosis Pitfalls

• Mature B-cell lymphomas (Burkitt, DLBCL) are typically TdT negative, distinguishing them from precursor lymphoblasts 3
• Mixed phenotype acute leukemia (MPAL): May express both lymphoid and myeloid markers; requires WHO 2022/ICC 2022 criteria for classification 7
• The absence of peroxidase-positive blasts is not a reliable indicator of lymphatic lineage; immunologic confirmation is essential 2

Clonality Assessment

Clonal rearrangements help confirm diagnosis 8:

• B-LBL: Clonal rearrangements of immunoglobulin heavy chain or light chain genes 5
• T-LBL: T-cell receptor γ or β chain gene rearrangements (though not helpful for lineage assignment) 5